All News
What happens when RA patients only on csDMARDs want to stop their meds?
in BIO-FLARE, only half flared within 6mo of stopping all csDMARDs suddenly. They’ve got a clinical predictive model. Many milder patients ask, and could benefit!
#EULAR2024 POS0068 John Isaacs @RheumNow https://t.co/B7ZjP5Pj70
Links:
David Liew drdavidliew ( View Tweet)
#EULAR2024 OP0206 In a cohort study, of pts with #lupus nephritis, 81% tapered IS ~32 mths post-renal response. Of this, 17% flared. Strategies for safe tapering: ensure CR is achieved, low SLEDAI-2K at 12mths, low SLEDAI-2K & on HCQ at the time of tapering initiation @RheumNow https://t.co/hAMAdsL7Jn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Risk of developing RA increased in antibody double-positive and single-positive compared to seronegative individuals. Highest risk in double-positive in first year. Single-positive increased risk of RA for up to five years after testing. In double-positive the risk remained… https://t.co/XLDHK4d4AE https://t.co/3Ek8knGExU
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Biosimilar uptake across the world.
Interesting that rich countries use more biosimilars - presumably because they have bargaining power - and that means they can access even better pricing.
#EULAR2024 POS0597 Leiden @RheumNow https://t.co/wZgA0JH5uu
David Liew drdavidliew ( View Tweet)
Still a long way but fascinating re: computer vision of hand movement from @vincevenerito @ThomasHugle.
Proof of concept training set shows decent correlation with DAS28-LDA & HAQ-DI. Much more work needed but the promise for telehealth is enticing
#EULAR2024 POS0607 @RheumNow https://t.co/iXsdn9fvuH
David Liew drdavidliew ( View Tweet)
Swedish/Danish cohort study in PsA
17000+ bionaïve 8000+ TNFi & 2000+ other MoA
Overall non melanoma skin cancer rate 651
(505 BCC & 87 SCC)
TNFi treated pts:
HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50)
HR 1.19 NMSC vs. other MoA (ns)
#EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6
Aurelie Najm AurelieRheumo ( View Tweet)
“One way to get rid of TDM is to get more drugs, and that’s what we’re doing”
- Gertjan Wolbink, the godfather of rheumatology therapeutic drug monitoring (TDM)
#EULAR2024 @RheumNow https://t.co/SYM8hjMMPJ
David Liew drdavidliew ( View Tweet)
TYK2i RCT 290 pts 12 wks in active PSA
TAK-279 15mg 30 mg 53% 54% vs PBO 29%
ACR 50 15mg 30 mg 26% 26% vs. PBO 10%response PASI 75 30 mg 46% vs. 15m 28% PBO 15%
Safety profile acceptable
Abstr#OP0138 #EULAR2024 @RheumNow https://t.co/thNuwvUgQp
Aurelie Najm AurelieRheumo ( View Tweet)
Elegant talk of #interferon #gamma in
#pyoderma #gangrenosum
Vs #PG + #pyogenic #arthritis +#acne
#autoinflammatory #syndromes #Papa syn
IL18 differences between PG alone and together in syndrome
#JAKi May be helpful
#EULAR2024 @eular_org @RheumNow @ARD_BMJ @ACR_Journals https://t.co/plYldVdolS
Links:
Janet Pope Janetbirdope ( View Tweet)
In the ‘why therapeutic drug monitoring’ debate, we’ve heard a lot about TDM utility, but the con argument is interesting.
Desiree van der Heijde compares TDM to IL-6 levels, which never displaced her DAS
then puts up some confronting points. Interesting
#EULAR2024 @RheumNow https://t.co/7zomungi3e
Links:
David Liew drdavidliew ( View Tweet)
I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial.
Would love to eventually see:
- H2H comparative effect vs toci, secukinumab
- structural outcomes
- long-term safety
#EULAR2024 PBA0001 @RheumNow https://t.co/pHZgCKsoA9 https://t.co/5BxCkkLPti
Links:
- https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
- https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
- https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
- https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
- https://twitter.com/drdavidliew/status/1801196482995101974
David Liew drdavidliew ( View Tweet)
#EULAR2024 POS0152 How prevalent is severe refractory #lupus? Multicentre cohort in Asia defined this as SLEDAI-2K=>10 + on GC + immunosuppressant. One in 7 met this definition, assoc w high activity & low T2T achievement. Useful for sample size calc for clinical study @RheumNow https://t.co/bq4gxX7kjI
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0191 Development and validation of plasma biomarkers to predict #lupus flare in the next 12 weeks. Quick turnover results. Need to focus on steps to bring these novel tools from bench to clinical practice @RheumNow https://t.co/64EppGI7bv
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
OP0201- clinical characteristics of pts failing ≥2 b/tsDMARDs
D2T RA pts characterised by
⏰ Earlier disease
⏰ Later initiation of DMARD therapy
Discontinuation of drugs mainly due to inefficacy regardless of number of drug lines or MOAs used
#EULAR2024 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2024 OP0008 Phase 2 #Sjogren RCT Iscalimumab, anti-CD40mAb in two cohorts (1=High systemic activity; 2=High symptom burden but low systemic) showed sustained improvement in ESSDAI & ESSPRI at 48wks in ISC-ISC group, as well as those switched at 24wks from PBO-ISC @RheumNow https://t.co/GuifDHA0lK
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0089 Promising data from Phase 2 RCT on dual blockade depletion & BAFF-R-i, Ianalumab in #lupus. After 24 wks double-blind, sustained response (SRI-4 + Pred ≤5mg/d or ≤ BL dose) was seen in IAN-IAN group while PBO-IAN improved in open label phase at 48wks @RheumNow https://t.co/MUo76ii4vB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
12-week ARGO Phase 2 trial data of IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit–risk profile. It met… https://t.co/4wj222FkzP https://t.co/ipUSjKvpuB
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
OP0140-When should we give #pneumococcal #vaccine to pts starting MTX?
Study in RA:PCV13 vaccine given 1 month BEFORE starting MTX leads to higher immunological response at 1m, vs pts vaccinated simultaneously w MTX
⏩Vaccinate patients before starting MTX!
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
When patients say their joints are swollen, what does it mean?
Easy to dismiss it as a symptom, but this clinically suspect arthralgia cohort from Leiden shows:
- some correlation with MRI/USS findings
- predicts RA development
still worthwhile!
#EULAR2024 POS0609 @RheumNow https://t.co/dw2p5Eo26C
David Liew drdavidliew ( View Tweet)
#Editors Picks @eular_org @ARD_BMJ @ACR_Journals
Can #rheumatologists effectively #dx of #ankylosing #spondylitis?
👍
552 pts - 1/3 axSpA w high certainty
Certainty of #dx changed over time
2 features
#sacroileitis
good #nSAID response
#EULAR2024 @RheumNow https://t.co/NN3GZTmgn9
Links:
Janet Pope Janetbirdope ( View Tweet)